3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Skin Neoplasms
3
Melanoma
3
Head and Neck Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Glioblastoma
2
Colorectal Neoplasms
2
Advanced Malignancies
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Recurrent Squamous Cell Carcinoma of Head
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Myelodysplastic Syndromes
1
Interventions
pembrolizumab
26
Gemcitabine
20
Cisplatin
12
Nivolumab
11
Carboplatin
8
Paclitaxel
7
Docetaxel
7
atezolizumab
6
durvalumab
5
Radiotherapy
5
fludarabine
4
enfortumab vedotin
4
Ipilimumab
4
Cyclophosphamide
4
Vorinostat
3
Magnetic Resonance Spectroscopy
3
Fluorouracil
3
Filgrastim
3
Doxorubicin
3
zimberelimab
2
vocimagene amiretrorepvec
2
tremelimumab
2
romidepsin
2
poly ICLC
2
infigratinib
2
erdafitinib
2
cc-486
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Urinary Bladder Neoplasms
×
cemiplimab
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled